Literature DB >> 11725817

Correlation of nicotinic receptor binding with clinical and neuropathological changes in Alzheimer's disease and dementia with Lewy bodies.

M N Sabbagh1, R T Reid, L A Hansen, M Alford, L J Thal.   

Abstract

We investigated the relationship between the loss of nicotinic acetylcholine receptors (nAChR) and the cognitive decline or neuropathological changes seen in Alzheimer's Disease (AD) and dementia with Lewy bodies (DLB). Midfrontal (MF) cortex of 31 AD, 24 DLB and 11 non-demented controls was examined. Total plaque (TP), neuritic plaque (NP) and neurofibrillary tangle (NFT) counts were obtained. NAChR binding was assayed using 3H-epibatidine [3H-EPI]. Last Blessed Information-Memory-Concentration scores (BIMC), Mini-Mental State Examination (MMSE), Mattis Dementia Rating Scale (DRS) scores were collected. There were no correlations between 3H-EPI binding and TP, NP, NFTs counts in either AD or DLB. Last BIMC, MMSE, DRS scores did not correlate with 3H-EPI binding in AD or DLB. Thus, decline in cognitive function does not correlate with loss of nAChR in DLB or AD at the end of life suggesting that later in these diseases, loss of nAChR binding is not a reliable marker of cognitive function in AD or DLB. Loss of nAChR activity does not appear to be related to plaques or NFTs in AD or DLB.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11725817     DOI: 10.1007/s007020170004

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  5 in total

1.  The N-butylcarbamate derivative of galantamine acts as an allosteric potentiating ligand on alpha7 nicotinic receptors in hippocampal neurons: clinical implications for treatment of Alzheimer's disease.

Authors:  Rodica V Popa; Edna F R Pereira; Cristiane Lopes; Alfred Maelicke; Edson X Albuquerque
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

2.  Alpha4beta2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 single-photon-emission computed tomography.

Authors:  J T O'Brien; S J Colloby; S Pakrasi; E K Perry; S L Pimlott; D J Wyper; I G McKeith; E D Williams
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-11-29       Impact factor: 10.154

3.  Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro.

Authors:  Richard T Reid; Marwan N Sabbagh
Journal:  J Neural Transm (Vienna)       Date:  2008-08-26       Impact factor: 3.575

Review 4.  The nicotinic acetylcholine receptor: smoking and Alzheimer's disease revisited.

Authors:  Mona Mehta; Abdu Adem; Maninder S Kahlon; Marwan N Sabbagh
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01

Review 5.  Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.

Authors:  Steven D Buckingham; Andrew K Jones; Laurence A Brown; David B Sattelle
Journal:  Pharmacol Rev       Date:  2009-03-16       Impact factor: 25.468

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.